Core Viewpoint - Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an Investor Webinar to discuss their innovative beverage designed to accelerate alcohol metabolism and reduce hangover symptoms, highlighting a significant investment opportunity [1][2][3]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][7]. - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales from the unbuzzd beverage until total payments reach $250 million, after which the royalty will decrease to 3% [7]. Product Details - Unbuzzd is a scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms [1][5]. - The product is backed by a double-blind, placebo-controlled clinical trial demonstrating that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [5]. - Participants reported significant improvements in alertness and reductions in perceived impairment and hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [5][6]. Investment Opportunity - Unbuzzd Wellness Inc. is currently offering a Regulation D 506(c) investment opportunity, aiming to raise up to $5 million to support its expansion plans and potential initial public offering [3]. - The webinar will provide insights into the company's strategies for increasing direct-to-consumer, distributor, and retail sales [2][3].

Company Overview - Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [2] - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical development [2] Analyst Coverage - Kingswood Capital Partners has initiated coverage of Quantum BioPharma with a BUY rating and a price target of US$45, contingent on successful Phase 2 and 3 trials of Lucid-MS between 2026 and 2028, with a commercial launch anticipated in 2029 [1] - The lead analyst for this report is Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners [1] Financial Interests - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is associated with the unbuzzd™ product, and is entitled to 7% royalty payments on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% indefinitely [2]

Corporate Updates - Quantum BioPharma Ltd. is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][5] - The company has drug candidates at various stages of development, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation associated with multiple sclerosis [5] Debt Settlement - On August 12, 2025, the company settled outstanding debt of $26,812.50 USD with a creditor by converting it into 1,102 Class B Shares at a price of $24.33 USD per share [2] Grant of Restricted Stock Units - On August 15, 2025, the company granted 800 restricted stock units (RSUs) each to two Clinical Advisors, Peter Stys and Jack Antel, with specific vesting conditions tied to regulatory filings [3][8] - The RSUs and Creditor Shares are subject to a statutory hold period of four months and one day [3] Advisory Board Changes - The company terminated the Board Advisor Agreement with Kevin Malone effective August 15, 2025, resulting in his departure from the advisory role [4] Strategic Investments - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the OTC version of its product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty will decrease to 3% [5] - The company also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [5]

Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral formulation of Lucid-MS, which will be used in the upcoming Phase 2 clinical trial for multiple sclerosis (MS) [1][3] - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound that has shown potential in preclinical models to prevent demyelination, a key characteristic of MS [2][4] - The company is preparing an Investigational New Drug (IND) application with the FDA as part of its clinical development strategy for Lucid-MS [3] Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders and metabolic disorders, with a portfolio that includes drug candidates at various stages of development [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty will drop to 3% [4] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

Company Overview - Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4] - The company is advancing its lead compound, Lucid-MS, which is a patented new chemical entity aimed at preventing and reversing myelin degradation, a key mechanism in multiple sclerosis (MS) [4] Research and Development - A joint clinical study with Massachusetts General Hospital (MGH) is evaluating the PET tracer [F]3F4AP, which has shown the ability to detect differences across lesions in MS patients that are not visible through conventional MRI [2][3] - The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, indicates that the PET tracer could serve as a significant biomarker for monitoring demyelination and myelin integrity in MS patients [2][3] Clinical Implications - The ongoing collaborative study aims to further assess the imaging agent's potential to demonstrate the effectiveness of Quantum BioPharma's investigational drug, Lucid-21-302, which is designed to protect the myelin sheath in MS [4] - Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, emphasized the promising nature of the PET tracer as a biomarker for MS lesions [4] Financial and Strategic Position - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of unbuzzd™, with a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

Core Insights - Quantum BioPharma Ltd. has received a clinical study report (CSR) confirming the safety and tolerability of its compound Lucid-MS in a Phase 1 trial involving healthy participants [1][3][4] - Lucid-MS is a first-in-class neuroprotective compound aimed at treating multiple sclerosis (MS) and has demonstrated the ability to prevent demyelination in preclinical models [2][5] - The company is preparing to advance the clinical development of Lucid-MS towards efficacy trials in MS patients following the positive CSR results [4][5] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, in its portfolio [5] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial properties [5]

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities in a market manipulation lawsuit, alleging damages exceeding $700 million USD due to "spoofing" techniques that artificially depressed its stock price [1][2][4]. Legal Proceedings - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants engaged in market manipulation that violated the Securities Exchange Act of 1934 [2]. - Quantum BioPharma's amended complaint was filed on May 31, 2025, in response to the defendants' memorandum of law filed on June 16, 2025 [2][3]. Financial Implications - Quantum BioPharma is seeking over $700 million USD in damages due to the alleged market manipulation [2]. - The company's stock was trading over $460 USD per share in January 2020, with a market capitalization approaching $1 billion USD [5]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted an extensive investigation and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Background - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement that could yield up to $250 million [10].

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities, alleging market manipulation that harmed the company's stock price and seeking over $700 million in damages [1][2]. Legal Proceedings - The company filed an amended complaint on May 31, 2025, alleging that the defendants engaged in market manipulation schemes violating the Securities Exchange Act of 1934 [2]. - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants used "spoofing" techniques to manipulate Quantum BioPharma's share price [2][4]. - The company has made all relevant legal documents available on its website for public access [3]. Financial Impact - Quantum BioPharma's stock was trading over $460 per share in January 2020, with a market capitalization nearing $1 billion [5]. - The company is seeking damages exceeding $700 million due to the alleged manipulation, which it claims has significantly harmed both the company and its investors [2][4]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted extensive investigations and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [10]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenue [10].

Core Viewpoint - Quantum BioPharma Ltd. announced that its subsidiary, Unbuzzd Wellness Inc., is launching a Regulation D 506(c) offering to raise up to US$5 million for growth and a potential initial public offering, which will not dilute Quantum BioPharma shareholders [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [6]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has an agreement for royalty payments of 7% of sales from Unbuzzd until total payments reach US$250 million, after which the royalty rate drops to 3% [6]. Product Information - Unbuzzd is a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, developed by a team with expertise in pharmacology and medicine [8][9]. - Clinical trials have shown that Unbuzzd can reduce blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, improve alertness, and lessen hangover symptoms significantly [10][13]. Capital Raising Strategy - Unbuzzd has partnered with MZ Digital and Dealmaker to conduct the capital raise campaign, allowing investments through traditional and cryptocurrency payments [3]. - The offering aims to support direct-to-consumer, distributor, and retail expansion plans for Unbuzzd [5].